Eribulin in advanced liposarcoma and leiomyosarcoma.

about

Atypical lipomatous tumor in the ligamentum teres of liver: A case report and review of the literature

P2860

Q58551501-D76D6F63-E277-48D2-9CAE-71114991F8A9

P2860

Eribulin in advanced liposarcoma and leiomyosarcoma.

Item

http://www.wikidata.org/entity/Q38722807

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Eribulin in advanced liposarcoma and leiomyosarcoma.

@en

type

Item

label

Eribulin in advanced liposarcoma and leiomyosarcoma.

@en

prefLabel

Eribulin in advanced liposarcoma and leiomyosarcoma.

@en

P1476

Eribulin in advanced liposarcoma and leiomyosarcoma.

@en

P2093

Charlotte Benson

http://www.w3.org/2001/XMLSchema#string

Elisabetta Setola

http://www.w3.org/2001/XMLSchema#string

Emanuela Palmerini

http://www.w3.org/2001/XMLSchema#string

Jonathan Noujaim

http://www.w3.org/2001/XMLSchema#string

Sant Chawla

http://www.w3.org/2001/XMLSchema#string

P2860

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Differential sensitivity of liposarcoma subtypes to chemotherapy.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

P304

717-723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1344098

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robin L Jones

P577

2017-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28621163

http://www.w3.org/2001/XMLSchema#string

Eribulin in advanced liposarcoma and leiomyosarcoma.

about

P2860

P2860

Eribulin in advanced liposarcoma and leiomyosarcoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698